Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897
- Determine if polymorphisms resulting in greater activation of cyclophosphamide (CYP2B6,
CYP3A4, and CYP3A5) are associated with disease-free survival and treatment toxicities
in women with breast cancer.
- Determine if polymorphisms resulting in less production of quinone-related oxidative
damage of doxorubicin hydrochloride (NQO1, NQO2, NOS2, NOS3, CBR3) are associated with
disease-free survival and treatment toxicities in these patients.
OUTLINE: This is a multicenter study.
Tissue samples archived on clinical trial SWOG-8897 are genotyped for polymorphisms in the
CYP3A4, CYP3A5, CYP2B6, NQO1, NQO2, NOS2, NOS3, and CBR3 genes by matrix-assisted laser
desorption ionization-time-of-flight mass spectrometry. Variant alleles are correlated with
PROJECTED ACCRUAL: A total of 1,577 patients will be accrued for this study.
Differences in outcome according to common variant alleles
Christine B. Ambrosone, PhD
Roswell Park Cancer Institute
United States: Federal Government